Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

SELL
$40.25 - $52.99 $28,175 - $37,093
-700 Reduced 51.47%
660 $27,000
Q4 2023

Jan 31, 2024

SELL
$48.48 - $57.85 $94,439 - $112,691
-1,948 Reduced 58.89%
1,360 $70,000
Q3 2023

Oct 25, 2023

BUY
$57.89 - $64.73 $112,769 - $126,094
1,948 Added 143.24%
3,308 $192,000
Q2 2023

Jul 24, 2023

SELL
$63.71 - $70.74 $42,685 - $47,395
-670 Reduced 33.0%
1,360 $87,000
Q1 2023

May 01, 2023

BUY
$65.71 - $74.53 $66,695 - $75,647
1,015 Added 100.0%
2,030 $138,000
Q3 2022

Oct 31, 2022

SELL
$0.13 - $76.84 $407 - $240,893
-3,135 Reduced 75.54%
1,015 $73,000
Q2 2022

Aug 10, 2022

BUY
$72.62 - $79.98 $91,428 - $100,694
1,259 Added 43.55%
4,150 $320,000
Q1 2022

May 02, 2022

BUY
$61.48 - $73.72 $156,220 - $187,322
2,541 Added 726.0%
2,891 $213,000
Q4 2021

Feb 02, 2022

SELL
$53.63 - $62.52 $38,559 - $44,951
-719 Reduced 67.26%
350 $22,000
Q3 2021

Nov 16, 2021

BUY
$59.17 - $69.31 $63,252 - $74,092
1,069 New
1,069 $63,000
Q3 2019

Nov 12, 2019

SELL
$42.77 - $50.71 $114,238 - $135,446
-2,671 Closed
0 $0
Q2 2019

Aug 08, 2019

BUY
$44.62 - $49.34 $119,180 - $131,787
2,671 New
2,671 $120,000
Q4 2018

Feb 13, 2019

SELL
$48.76 - $63.23 $567,566 - $735,997
-11,640 Closed
0 $0
Q3 2018

Nov 08, 2018

BUY
$55.19 - $62.25 $379,596 - $428,155
6,878 Added 144.44%
11,640 $723,000
Q2 2018

Aug 01, 2018

BUY
$50.53 - $62.98 $233,094 - $290,526
4,613 Added 3095.97%
4,762 $262,000
Q1 2018

May 02, 2018

BUY
$59.92 - $68.98 $8,928 - $10,278
149 New
149 $9,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Migdal Insurance & Financial Holdings Ltd. Portfolio

Follow Migdal Insurance & Financial Holdings Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.